Summary

Eli Lilly and Novo Nordisk compete with FDA-approved GLP-1 drugs for weight loss — injectables and pills — but a KFF survey shows 55% of insured users find these drugs difficult to afford. Prescriber preference surveys confirm clinical efficacy is not the limiting factor. Consequently, cost and formulary structure — not clinical performance alone — may determine long-term market share.

Access Impact

Both companies hold regulatory approval in the US. However, many health plans exclude GLP-1s from coverage when prescribed for obesity rather than type 2 diabetes or cardiovascular risk reduction. This creates a split-access structure: the same molecule, two different coverage decisions, depending on the indication. This distinction is directly captured in MARA’s Budget Impact and Coverage domains, where payer willingness to reimburse is assessed independently of clinical approval status.

Budget Impact

Monthly costs without insurance average $900–$1,400 for injectables. Even insured patients face significant out-of-pocket exposure — 55% of GLP-1 users with insurance report cost as a barrier to treatment. Spherix poll data found that 74% of patient discontinuations are cost-driven, not linked to side effects or lack of efficacy. This discontinuation rate has direct implications for real-world effectiveness estimates and for the long-term budget impact modelling that payers use to set formulary access criteria.

Cost-Effectiveness

ICER has previously assessed semaglutide and found its cost-effectiveness borderline at list price. At negotiated or discounted prices, the threshold analysis changes. The Wegovy pill and Foundayo are now priced at $149/month list price — lower than injectables — and the Spherix poll data shows physicians rate oral Wegovy highest for affordability. This shift toward cheaper delivery mechanisms may move the cost-effectiveness picture in ways that affect reimbursement criteria going forward.

Coverage and Formulary Access

Formulary coverage for GLP-1s in obesity remains fragmented across the US market. The TrumpRx initiative provides discounted access but does not address systematic formulary exclusion. Medicare coverage for weight loss indications remains limited. Without a consistent national reimbursement standard, market access for GLP-1 obesity drugs is determined payer by payer, plan by plan. For any portfolio or M&A assessment involving these assets, that fragmentation represents a structural access risk that clinical trial data cannot resolve.

Risk Signal

The market access risk here is not scientific — it is structural. FDA approval does not create coverage, and coverage does not guarantee affordability. For investors evaluating GLP-1 assets, the limiting variable is not efficacy but payer behaviour at scale. What independent, defensible benchmark are you using to assess that payer risk before committing capital?

#MarketAccess #HTA #MARArating #GLP1 #Obesity

Explore GLP-1 market access independent assessment: https://mararating.com/market-access-pharma/

Explore MARA drug ratings: https://mararating.com/mara-ratings-list

This drug is part of MARA’s coverage of market access risk in obesity.